Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Inclusion Criteria:

• A history of migraine with or without aura consistent with a diagnosis according tothe International Classification of Headache Disorders (ICHD-3) for at least 6months.

• By history, the participant's migraines typically last between 3 and 72 hours ifuntreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom.

• History of 1 to 14 migraine attacks per month with moderate to severe headache ineach of the 2 months prior to screening (Visit 1).

• Current or past use of at least 1 oral medication (over-the-counter medication orprescription medication) for the acute treatment of migraine.

• For main study participants, treatment of a qualifying migraine with single-blindplacebo during the screening period and completion of 2-hour headache painassessment.

• Weight is ≥ 20 kg (44 pounds) and < 135 kg (298 pounds)

• Per investigator judgment, participant is able to swallow or can learn to swallowstudy intervention.

• The participant is able to understand and complete the study questionnaires andeDiary. Participants who need assistance with reading the assessments may beassisted by a parent or guardian.

Exclusion Criteria:

• Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic,gastrointestinal, cardiovascular or neurologic disease.

• In the opinion of the investigator, other confounding pain syndromes, confoundingpsychiatric conditions, or other significant neurological disorders other thanmigraine.

• History of malignancy in the 5 years prior to Visit 1.

• History of any prior gastrointestinal conditions (eg, diarrhea syndromes,inflammatory bowel disease) that may affect the absorption or metabolism of thestudy intervention.

• Significant risk of self-harm, based on clinical interview and responses on theColumbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others; participantsmust be excluded if they report suicidal ideation with intent, with or without aplan, (ie, Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidalbehavior in the last 6 months prior to Visit 1 or Visit 2 assessments.

• At Visit 1, current alcohol or drug abuse or dependence per investigator's judgment.

• For main study participants, no headache at the 2-hour post dose assessment aftertaking single-blind placebo for a qualifying migraine during screening period (ie,placebo responder).

• A current diagnosis of chronic migraine as defined by ICHD-3

• Participants who overuse medication for migraine defined as use of opioids orbarbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 15 days/month or any combination of triptans,ergots, or simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 10 days/month inthe 3 months prior to Visit 1 per investigator's judgment.

• Difficulty distinguishing migraine headache from tension-type or other headaches.

• Has a history of migraine aura with diplopia or impairment of level ofconsciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3.

• Has a current diagnosis of new persistent daily headache, trigeminal autonomiccephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3

• Required in-hospital (excluding emergency department visits) treatment for migraines 3 or more times in the 6 months prior to Visit 1.

• Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice)that is on the list of prohibited concomitant medications that cannot bediscontinued or switched to an allowable, alternative medication at Visit 1.

• Previous exposure, within the last 6 months, to injectable monoclonal antibodiesblocking the calcitonin gene-related peptide (CGRP) pathway

• History of hypersensitivity or clinically significant adverse reaction to a CGRPreceptor antagonist or hypersensitivity to any component of the study interventions,ubrogepant or placebo.

• Currently participating or has participated in a study with an investigationalcompound or device within 30 days prior to Visit 1